Updated strategies in the treatment of benign diseases-a patterns of care study of the german cooperative group on benign diseases

Jan Kriz, Heinrich M Seegenschmiedt, Amelie Bartels, Oliver Micke, Ralph Muecke, Ulrich Schaefer, Uwe Haverkamp, Hans T Eich, Jan Kriz, Heinrich M Seegenschmiedt, Amelie Bartels, Oliver Micke, Ralph Muecke, Ulrich Schaefer, Uwe Haverkamp, Hans T Eich

Abstract

Purpose: Radiation therapy (RT) is a common treatment for benign diseases in Germany. Because the treatment concepts are inconsistent, we conducted this pattern-of-care study on behalf of the German Cooperative Group on Benign Diseases to evaluate treatment standards in Germany.

Methods and materials: Questionnaires were mailed to all radiation therapy facilities in Germany. We assessed the treatment equipment, annual number of patients, treatment indications, and, in particular, treatment strategies in patients with benign diseases in 2014.

Results: We evaluated questionnaires returned by 116 participating institutions, of which 41 were ambulatory health care centers, 28 were private institutions, 27 were community hospitals, and 20 were university hospitals. On average, 2 linac accelerators and 2 megavoltage units were available in each institution. In 2014, a total of 36,830 patients were treated for benign diseases: 16,989 for degenerative diseases (peritendinitis humeroscapularis n = 2691; epicondylitis humeri n = 3788; heel spur n = 10,510); 14,936 for osteoarthritis (coxarthrosis n = 2230; gonarthrosis n = 2623; omarthrosis n = 2691; rhizarthrosis n = 2440; polyarthrosis n = 2297; others n = 2655); 1563 for hyperproliferative diseases (morbus Dupuytren n = 960; morbus Ledderhose n = 441; keloids n = 139; pterygium of the conjunctiva n = 3; other hyperproliferative diseases n = 20); 2440 for functional disorders (gynecomastia n = 843; Graves' disease n = 205; lymphatic fistula n = 178; heterotopic ossification prophylaxis n = 1214); 859 for stereotactic RT in the central nervous system (arteriovenous malformation n = 53; meningioma n = 425; acoustic neuroma n = 201; pituitary adenoma n = 131; others n = 49), and 43 for rare indications (pigmented villonodular synovitis n = 20 or vertebral hemangioma n = 23). The mean whole dose was <10 Gy in the treatment of degenerative disorders, 25 Gy for hyperproliferative diseases, 15 Gy for functional disorders, and <50 Gy for stereotactic RT.

Conclusions: In 2014, RT had an important role in the treatment of benign diseases. Because treatment concepts are inherent, we recommend treatment based on the guidelines written by the German Cooperative Group on Benign Diseases.

Figures

Figure 1
Figure 1
Participating centers in Germany.

References

    1. Order S., Donaldson S.S. 2nd ed. Springer; New York, NY: 1998. Radiotherapy of Benign Diseases.
    1. Leer J., van Houtte P., Daelaar J. Indications and treatment schedules for irradiation of benign diseases: A survey. Radiother Oncol. 1998;48:249–257.
    1. Heyd R., Micke O., Berger B. Radiation therapy in the treatment of pigmented villonodular synovitis (PVNS). Results of a national patterns of care study. Int J Radiat Oncol Biol Phys. 2010;78:199–204.
    1. Kriz J., Eich H.T., Bruns F. Radiotherapy in Langerhans cell histiocytosis—a rare indication in a rare disease. Radiat Oncol. 2013;9:233.
    1. Neu B., Sautter V., Momm F. Radiotherapy for prevention and therapy of gynecomastia due to antiandrogen treatment in prostate cancer patients: A patterns of care study. Strahlenther Onkol. 2011;187:771–777.
    1. Muecke R., Seegenschmiedt M.H., Heyd R. Radiotherapy in painful gonarthrosis. Results of a National Patterns of care study. Strahlenther Onkol. 2010;186:7–17.
    1. Seegenschmiedt M.H., Katalinic A., Makoski H. Radiation therapy for benign diseases: Patterns of care study in Germany. Int J Radiat Oncol Biol Phys. 2000;47:195–202.
    1. Heyd R., Micke O., Surholt C. Radiation therapy for Gorham Stout Syndrome: Results of a national patterns of care study and literature review. Int J Radiat Oncol Biol Phys. 2011;81:179–185.
    1. Micke O., Seegenschmiedt M.H. Radiation therapy for aggressive fibromatosis (desmoid tumors): Results of a national patterns of care study. Int J Radiat Oncol Biol Phys. 2005;61:882–891.
    1. Reichl B., Block A., Schäfer U. DEGRO practical guidelines for radiotherapy of non-malignant disorders: Part I: Physical principles, radiobiological mechanisms, and radiogenic risk. Strahlenther Onkol. 2015;191:701–709.
    1. Ott O., Niewald M., Weitmann H. DEGRO guidelines for the radiotherapy of non-malignant disorders. Part II: Painful degenerative skeletal disorders. Strahlenther Onkol. 2015;191:1–6.
    1. Seegenschmiedt M.H., Micke O., Niewald M. DEGRO guidelines for the radiotherapy of non-malignant disorders: Part III: Hyperproliferative disorders. Strahlenther Onkol. 2015;191:541–548.
    1. Reinartz G., Eich H.T., Pohl F. DEGRO practical guidelines for the radiotherapy of non-malignant disorders—Part IV: Symptomatic functional disorders. Strahlenther Onkol. 2015;191:295–302.
    1. Gregoritch S.J., Chadha M., Pellegrini V.D., Rubin P., Kantorowitz D.A. Randomized trial comparing preoperative versus postoperative irradiation for prevention of heterotopic ossification following prosthetic total hip replacement: Preliminary results. Int J Radiat Oncol Biol Phys. 1994;30:55–62.
    1. Knelles D., Barthel T., Karrer A., Kraus U., Eulert J., Kolbl O. Prevention of heterotopic ossification after total hip replacement: A prospective, randomized study using acetylsalicyl acid, indomethacin and fractional or single dose irradiation. J Bone Joint Surg Br. 1997;79:596–602.
    1. Kolbl O., Knelles D., Barthel T., Raunecker F., Flentje M., Eulert J. Preoperative irradiation versus the use of nonsteroidal anti-inflammatory drugs for prevention of heterotopic ossification following total hip replacement: The results of a randomized trial. Int J Radiat Oncol Biol Phys. 1998;42:397–401.
    1. Seegenschmiedt M.H., Martus P., Goldmann A.R., Wolfel R., Keilholz L., Sauer R. Preoperative versus postoperative radiotherapy for prevention of heterotopic ossification: First results of a randomized trial in high-risk patients. Int J Radiat Oncol Biol Phys. 1994;30:63–73.
    1. Seegenschmiedt M.H., Keilholz L., Martus P. Prevention of heterotopic ossification about the hip: Final results of two randomized trials in 410 patients using either preoperative or postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 1997;39:161–171.
    1. Betz N., Ott O.J., Adamietz B., Sauer R., Fietkau R., Keilholz L. Radiotherapy in early-stage Dupuytren's contracture. Long-term results after 13 years. Strahlenther Onkol. 2010;186:82–90.
    1. Micke O., Seegenschmiedt M.H. Consensus guidelines for radiation therapy of benign diseases: A multicentre approach in Germany. Int J Radiat Oncol Biol Phys. 2002;52:496–513.
    1. Micke O., Seegenschmiedt M.H. Radiotherapy in painful heel spurs (plantar fasciitis) – results of a national patterns of care study. Int J Radiat Oncol Biol Phys. 2004;58:828–843.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere